Brokerages expect Eagle Pharmaceuticals Inc (NASDAQ:EGRX) to announce earnings per share of $0.72 for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Eagle Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.73 and the lowest estimate coming in at $0.71. Eagle Pharmaceuticals reported earnings per share of $0.95 in the same quarter last year, which suggests a negative year-over-year growth rate of 24.2%. The business is scheduled to announce its next earnings report on Tuesday, August 6th.
On average, analysts expect that Eagle Pharmaceuticals will report full year earnings of $3.46 per share for the current year, with EPS estimates ranging from $3.38 to $3.59. For the next year, analysts expect that the business will post earnings of $4.11 per share, with EPS estimates ranging from $3.10 to $5.11. Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Eagle Pharmaceuticals.
Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.28. The company had revenue of $49.80 million for the quarter, compared to analyst estimates of $47.03 million. Eagle Pharmaceuticals had a net margin of 17.67% and a return on equity of 21.38%. Eagle Pharmaceuticals’s revenue was up 6.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.55 EPS.
Several brokerages have recently commented on EGRX. Cantor Fitzgerald restated a “hold” rating and issued a $58.00 price objective on shares of Eagle Pharmaceuticals in a report on Tuesday, May 7th. Zacks Investment Research raised shares of Eagle Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, May 13th. BidaskClub raised shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, April 25th. Mizuho reaffirmed a “hold” rating and issued a $50.00 target price on shares of Eagle Pharmaceuticals in a research report on Wednesday, April 24th. Finally, ValuEngine raised shares of Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, March 1st. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $65.17.
In other news, CEO Scott Tarriff sold 24,975 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $50.15, for a total value of $1,252,496.25. Following the completion of the transaction, the chief executive officer now owns 1,500,202 shares in the company, valued at approximately $75,235,130.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Douglas L. Braunstein sold 159,223 shares of the firm’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $56.81, for a total transaction of $9,045,458.63. The disclosure for this sale can be found here. Company insiders own 28.20% of the company’s stock.
A number of large investors have recently bought and sold shares of the business. Park West Asset Management LLC increased its holdings in Eagle Pharmaceuticals by 41.6% during the 4th quarter. Park West Asset Management LLC now owns 1,050,000 shares of the specialty pharmaceutical company’s stock valued at $42,304,000 after acquiring an additional 308,574 shares in the last quarter. Vanguard Group Inc. increased its holdings in Eagle Pharmaceuticals by 9.7% during the 3rd quarter. Vanguard Group Inc. now owns 674,951 shares of the specialty pharmaceutical company’s stock valued at $46,794,000 after acquiring an additional 59,474 shares in the last quarter. D. E. Shaw & Co. Inc. increased its holdings in Eagle Pharmaceuticals by 121.5% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 285,318 shares of the specialty pharmaceutical company’s stock valued at $11,495,000 after acquiring an additional 156,499 shares in the last quarter. Millennium Management LLC increased its holdings in Eagle Pharmaceuticals by 2,385.0% during the 4th quarter. Millennium Management LLC now owns 284,753 shares of the specialty pharmaceutical company’s stock valued at $11,473,000 after acquiring an additional 273,294 shares in the last quarter. Finally, Norges Bank purchased a new position in Eagle Pharmaceuticals during the 4th quarter valued at about $10,948,000. Hedge funds and other institutional investors own 94.96% of the company’s stock.
Shares of EGRX stock traded up $0.31 during trading hours on Friday, hitting $51.99. The company had a trading volume of 104,816 shares, compared to its average volume of 197,924. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.89 and a current ratio of 4.12. Eagle Pharmaceuticals has a fifty-two week low of $36.03 and a fifty-two week high of $85.66. The firm has a market cap of $710.82 million, a P/E ratio of 24.88 and a beta of 1.58.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL.
Recommended Story: Front-End Load
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.